General Approach of Haemostasis

Slides:



Advertisements
Similar presentations
Basic coagulation techniques and Quality control issues
Advertisements

TREATMENT Coagulopathy of Liver Failure. Fresh Frozen Plasma – Most effective way to correct hemostasis in patients with liver failure – Infusion (5-10mL/kg)
BLEEDING DISORDERS AN OVERVIEW WITH EMPHASIS ON EMERGENCIES.
Faculty of Allied Medical Science
General Approach of Haemostasis
Pre-analytical factors that can affect coag test results
Quantitative Fibrinogen Mr. Mohammed A. Jaber.  Fibrinogen assays are quantitative techniques to measure the amount of functional fibrinogen present.
Coagulation Time Tube Method Mr. Mohammed A. Jaber.
Bleeding time,clotting time, PT, and PTT
Approach to the Bleeding Patient
Dr msaiem Acquired Coagulation Disorders Dr Mohammed Saiem Al-dahr KAAU Faculty of Applied Medical Sciences.
Week 6: Secondary Hemostasis Plasmatic factors Plasmatic factors Intrinsic pathway Intrinsic pathway Extrinsic pathway Extrinsic pathway Specimen Specimen.
One Stage Factor V Assay
Tests to measure fibrin clot Lecture 9: General Approach in Investigation of Haemostasis.
Hemostasis and Blood Coagulation
MLAB Coagulation Keri Brophy-Martinez
Tests for the Evaluation of Lupus Anticoagulants Islamic University of Gaza.
General Approach of Haemostasis
Methods to Detect Red Cell Membrane Disorders
©2007 Wortham Laboratories, Inc.
Approach to Bleeding Disorders
APPROACH TO BLEEDING DISORDERS. History of Bleeding Spontaneous vs. trauma/surgery-induced Ecchymoses without known trauma Medications or nutritional.
MIXING STUDIES General Approach of Haemostasis
MLAB 1227-Coagulation Keri Brophy-Martinez Preanalytical Issues in Coagulation Testing.
  The prothrombin time is therefore the time required for the plasma to clot after an excess of thromboplastin and an optimal concentration of calcium.
In this exercise, two tests will be performed to screen for defective clotting factors. The formation of thrombin in the plasma samples will be inhibited.
APTT. Causes of prolonged aPTTs: 1.Spurious (common to many Coag tests): – dilution (saline, Tx), underfilled specimen, clotted, prolonged tourniquet.
Tests to Measure Fibrin formation Mr. Mohammed A. Jaber.
Investigation of Haemostasis MS. c. program Lab-9.
Activated Partial Thromboplastin Time (aPTT)
Preparation of blood components
Laboratory Testing in Coagulation Coagulation Keri Brophy-Martinez.
Factor Assays Robert Gosselin MT (ASCP), CLS.
1. Normal haemostasis Haemostasis is the process whereby haemorrhage following vascular injury is arrested. It depends on closely linked interaction.
Hemostasis Is a complex process which causes the bleeding process to stop. It refers to the process of keeping blood within a damaged blood vessel. Dependent.
University of North Carolina-Chapel Hill Division of Hematology
Chapter 17 Coagulation Testing
Chapter 23. Bleeding disorders associated with coagulopathy
Bleeding Tendency Dr. Mervat Khorshied Ass. Prof. of Clinical and Chemical Pathology.
Platelets. Fig Hemostasis the process by which the bleeding is stopped from broken vessels. steps involved: Vascular spasm. Platelets plug formation.
One-Stage Quantitative
Approach To Bleeding Disorders In Neonates
MLAB Coagulation Keri Brophy-Martinez
Pre-analytical factors that can affect coag test results
Activated Partial Thromboplastin Time (aPTT)
General Approach of Haemostasis
General Approach in Investigation of Hemostasis
One Stage Factor V Assay
General Approach in Investigation of Haemostasis
General Principles of Hemostasis Kristine Krafts, M.D.
Acquired coagulation disorders
General Approach in Investigation of Hemostasis
Methods to Detect Red Cell Membrane Disorders
University of North Carolina-Chapel Hill Division of Hematology
Mixing Studies-aPTT or PT 1:1 Mix
Activated Partial Thromboplastin Time (aPTT)
How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults  Arif H. Kamal, MD, Ayalew.
Intrinsic pathway Formation of prothombin activator is the central event in the clotting pathway For its formation the pathway that is initiated by.
Hemophilia By: Renee Marie Alta.
Coagulation Factor Assays
General Principles of Hemostasis Kristine Krafts, M.D.
Practical Hematology Lab Osmotic Fragility Test
Screening Tests Selection of reagents & Mixing studies
HAEMOPHILIA TREATMENT CENTRE
Principles of Coagulation Screening II
Practical Hematology Lab Osmotic Fragility Test
Blood Components Dosage And Their Administration
Practical Hematology Lab Osmotic Fragility Test
General Approach in Investigation of Haemostasis
Practical Blood Bank Lab 11 Cyroglobulin.
Presentation transcript:

General Approach of Haemostasis Lecture 7: Mixing Studies

Mixing studies: Mixing studies are tests performed on blood plasma used to distinguish factor deficiencies from factor inhibitors, such as lupus anticoagulant, or specific factor inhibitors, such as antibodies directed against factor VIII. Mixing studies take advantage of the fact that factor levels that are 50 percent of normal should give a normal Prothrombin time (PT) or Partial Thromboplastins time Mixing studies can help determine the appropriate next steps to take to diagnose the cause of an abnormal APTT or PT coagulation screening tests are relatively insensitive to protein concentration

Test method The patient plasma is mixed 1:1 with Normal pooled plasma that contains 100% of the normal factor level results in a level ≥ 50% in the mixture (say the patient has an activity of 0%; the average of 100% + 0% = 50%). Therefore, correction with mixing indicates factor deficiency; failure to correct indicates an inhibitor.

Test method Some inhibitors are time dependent. The clotting test performed immediately after the specimens are mixed may show correction because the antibody has not had time to inactivate the added factor (false positive). A test performed after the mixture is incubated for 2 hours at 37°C will show prolongation. Nonspecific inhibitors like the lupus anticoagulant usually are not time dependent; the immediate mixture will show prolongation. Many specific factor inhibitors are time dependent, and the inhibitor will not be detected unless the test is repeated after incubation (factor VIII inhibitors are notorious for this).

Reagents and Equipment Pooled Plasma - platelet-poor plasma from 20 or more healthy, male and female adult donors. Pooled plasma must be used to ensure approximately 100% of all factors are present. DO NOT Use a single-sourced normal plasma. DO NOT Use Lyophilized Normal Control. Other reagents required to perform the screen test(s) (i.e., PT or PTT). Quality Control The pooled plasma must be evaluated for the test to be performed and results must fall within the reference range or testing is repeated with a fresh aliquot of the pooled plasma.

Procedure Prepare a 1:2 dilution of patient plasma using pooled plasma as the diluents, by mixing equal volumes of each of the plasmas. (make sufficient quantities to run the test in duplicate) Label two test tubes for each test plasma to be re-tested (Mixture, NPP) Add 0.1 ml of patient plasma to 0.1 ml of NPP in one of the two labeled tube Carefully mix the plasmas using the pipette, aspirating and expelling the solution several times (avoid making bubbles). Transfer 0.1 mL of the diluted patient plasma to the second labeled test tube. Measure the APTT or PT for the mixed and incubated tube, and the control tube.

In cases where time and temperature dependent inhibitors are suspected, repeat testing should also be performed on incubated mixes: patient plasma – pooled plasma mix incubated for 1 to 2 hours at 37° C prior to testing. Mix patient plasma with pooled normal plasma in equal volumes in a plastic test tube. In two separate tubes, pipet a volume of patient plasma and a volume of pooled normal plasma. Incubate all 3 tubes for 1 to 2 hours at 37°C. Combine the incubated patient plasma tube and the incubated pooled normal plasma and use as the control tube. Measure the APTT or PT for the mixed and incubated tube, and the control tube.

Values Expected

Interpretation The first step when evaluating unexpected prolonged PT or PTT results is to rule out preanalytical interference, e.g., presence of contaminating heparin. If the APTT or PT is corrected by normal plasma, a factor deficiency is indicated. If the APTT or PT is not corrected by the addition of nor-mal plasma immediately, a strong inhibitor is indicated. A weak or time-dependent inhibitor is indicated by a prolonged APTT or PT following incubation at 37°C for 1 to 2 hours ( factor VIII inhibitor).

Interpretation 1:1 Mixing Study Results Not incubated Correction Table A Differentiation of Factor Deficiency and Inhibitors By Mixing Studies 1:1 Mixing Study Results Not incubated Incubated Factor deficiency Correction Immediate acting inhibitor No correction Time/temperature dependent inhibitor Correction (Falsely) Table adapted from McKenzie, S.,, Clinical l Laboratory Hematology, 2004, p. 790.

Possible Interpretations Coagulation Screen Results: PT prolonged PT mixing study results: PT corrects Most likely interpretation: Factor VII deficiency Probable cause(s): Early response to warfarin, early vitamin K deficiency Rare cause: Congenital factor VII deficit PTT prolonged PTT mixing study results: PTT corrects Factor deficit Factor VIII or IX (male) deficiency, or von Willebrand Disease (female) Possible cause Factor inhibitor PTT markedly prolonged (>200 seconds) Severe Contact Factor deficit Factor Prekallikrein, HMWK, XI, or XII PT and PTT prolonged PT & PTT mixing study results: PT and PTT correct Acquired, multiple factor deficiency DIC, Liver Disease, Vitamin K deficiency Possible cause: Warfarin therapy PTT slightly – moderately prolonged No correction Immediately reacting antibody inhibitor Lupus anticoagulant

Comment The antibody that inhibits factor VIII is most often a specific IgG antibody (temperature and time dependent) , which will cause only a slightly prolonged APTT on initial testing. If a factor VIII inhibitor is present, it is important to determine the initial level of factor activity because the development of an inhibitor complicates the management of a patient with hemophilia A when therapy involves AHF* concentrates. These should be monitored periodically. Repeating the mixing study with 4 parts patient sample and 1 part normal pooled plasma may increase the chance of detecting a weak inhibitor. *Antihemophilic factor (AHF ) : A commercially prepared source of factor VIII.

Notes: Be careful when thawing the pooled plasma because prolonged incubation at 37°C will selectively decrease Factor V, prolonging the results and making interpretation of the 1:1 mix test results difficult. The pooled normal plasma is stable for ~2 hours at room temperature. Initial test results for the pooled normal plasma must be within the reference range or the mix should be repeated with a fresh aliquot of pooled normal plasma.

Thank you http://site.iugaza.edu.ps/ialaswad/ http://site.iugaza.edu.ps/wael Next Lecture: Coagulation-instruments